Oppenheimer analyst Les Sulewski initiates coverage on CorMedix (NASDAQ: CRMD) with a Outperform rating and a price target of $15.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage